DELRAY BEACH, Fla., Feb. 17, 2025 /PRNewswire/ -- The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, ...

Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight. (Albany, US), October 23, ...

Butterfly Medical, developer of a proprietary minimally invasive solution for benign prostatic hyperplasia (BPH), today announced that it has received certification under the European Union Medical ...

ProVerum Limited is a company that has made significant strides with its development of the ProVee System, a minimally invasive solution specifically designed for treating benign prostatic hyperplasia ...

Benign Prostatic Hyperplasia: Causes, Symptoms, Diagnosis, and Treatments: By Anjali Srivastava Benign Prostatic Hyperplasia (BPH) is a common condition that affects many men as they age, involving ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Introduction: Do not endure frequent urinationWaking up multiple times at night to use the toilet, weak urine flow, and the ...

Butterfly Medical, developer of a minimally invasive solution for benign prostatic hyperplasia (BPH), has earned EU MDR ...

BPH prostate treatment market is evolving toward a more patient-focused, technology-driven ecosystem. As innovation in both pharmaceuticals and minimally invasive procedures accelerates, companies ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...